Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aimmune Therap (AIMT)

Aimmune Therap (AIMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,257,370
  • Shares Outstanding, K 65,450
  • Annual Sales, $ 0 K
  • Annual Income, $ -248,500 K
  • 60-Month Beta 1.76
  • Price/Sales 3,892.02
  • Price/Cash Flow N/A
  • Price/Book 12.55
Trade AIMT with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.33
  • Most Recent Earnings -1.06 on 07/30/20
  • Next Earnings Date 11/04/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.99
  • Number of Estimates 7
  • High Estimate -0.88
  • Low Estimate -1.23
  • Prior Year -1.03
  • Growth Rate Est. (year over year) +3.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.21 +0.82%
on 09/14/20
34.59 -0.29%
on 10/09/20
+0.29 (+0.85%)
since 09/11/20
3-Month
11.82 +191.79%
on 08/28/20
34.59 -0.29%
on 10/09/20
+18.81 (+119.96%)
since 07/10/20
52-Week
10.09 +241.82%
on 03/17/20
37.00 -6.78%
on 01/16/20
+9.94 (+40.49%)
since 10/11/19

Most Recent Stories

More News
Aimmune Presents New Clinical Data From Pooled Safety Analysis in Patients Treated With PALFORZIA® for up to ~3.5 Years

Aimmune Therapeutics, a Nestlé Health Science company developing and commercializing treatments for potentially life-threatening food allergies, today announced new clinical data from a pooled analysis...

AIMT : 34.49 (-0.29%)
Aimmune Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit: Portnoy Law Firm

Investors with losses are encouraged to contact the firm before November 21, 2020; click here to submit trade information

AIMT : 34.49 (-0.29%)
Life-Saving Advancements, Treatments Delivered by Companies Invested in Innovation

NetworkNewsWire Editorial Coverage : Innovation and breakthroughs in the biotech industry are essential to identifying and providing life-saving treatments. Companies that invest substantial amounts of...

KBLM : 4.99 (-17.52%)
ADAP : 1.6800 (+1.82%)
AIMT : 34.49 (-0.29%)
IMVT : 18.66 (-1.79%)
CDNA : 15.74 (-4.95%)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of AIMT, BMCH, BYFC, and CGIX Mergers

WILMINGTON, Del., Sept. 23, 2020 (GLOBE NEWSWIRE) --

AIMT : 34.49 (-0.29%)
BMCH : 53.68 (-3.24%)
BYFC : 1.3100 (-2.24%)
CGIX : 4.61 (-2.33%)
Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies

- Longitude Venture Partners IV will build on the Firm’s commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery -

AIMT : 34.49 (-0.29%)
ETNB : 14.62 (+0.62%)
AXNX : 57.32 (-2.57%)
CMPI : 10.50 (+0.19%)
INZY : 2.62 (unch)
MTEM : 0.4908 (-9.28%)
PSTX : 8.42 (-3.55%)
PCVX : 45.17 (-0.68%)
MERGER INVESTIGATION ALERT: Halper Sadeh LLP Reminds Investors About Its Ongoing Investigations; Shareholders are Encouraged to Contact the Firm – MNTA, VRTU, AIMT, MXIM

NEW YORK, NY / ACCESSWIRE / September 20, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) concerning potential violations of the...

MNTA : 52.48 (-0.02%)
VRTU : 51.33 (+0.03%)
AIMT : 34.49 (-0.29%)
MXIM : 103.14 (-1.18%)
Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., (NASDAQ:AIMT), Akcea Therapeutics, Inc., (NASDAQ:AKCA), BMC Stock Holdings, Inc., (NASDAQ:BMCH), and Cancer Genetics, Inc., (NASDAQ:CGIX)

NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) --

AIMT : 34.49 (-0.29%)
AKCA : 18.17 (+0.17%)
BMCH : 53.68 (-3.24%)
BLDR : 81.70 (-0.21%)
CGIX : 4.61 (-2.33%)
ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm – AIMT, AKCA, PTI

NEW YORK, NY / ACCESSWIRE / September 12, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) concerning potential violations...

AIMT : 34.49 (-0.29%)
AKCA : 18.17 (+0.17%)
PTI : 1.1100 (-3.48%)
INVESTIGATION ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm – RST, CBMG, AIMT, AKCA

Halper Sadeh LLP, a global investor rights law firm, is investigating:

RST : 29.99 (unch)
CBMG : 19.75 (unch)
AIMT : 34.49 (-0.29%)
AKCA : 18.17 (+0.17%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm – MNTA, BMCH, RST, AIMT

NEW YORK, NY / ACCESSWIRE / September 5, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) concerning potential violations...

MNTA : 52.48 (-0.02%)
BMCH : 53.68 (-3.24%)
RST : 29.99 (unch)
AIMT : 34.49 (-0.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 34.59
1st Resistance Point 34.54
Last Price 34.49
1st Support Level 34.46
2nd Support Level 34.43
3rd Support Level N/A

See More

52-Week High 37.00
Last Price 34.49
Fibonacci 61.8% 26.72
Fibonacci 50% 23.55
Fibonacci 38.2% 20.37
52-Week Low 10.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar